KP
Kiniksa Pharmaceuticals Ltd
🇺🇸XNAS.KNSAUnited StatesHealthcare
$76.97USDup +1.86 (+2.48%)After-hoursDelayed8:10 PM
Price$76.97+1.86 (+2.48%)
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- GB00BRXB0C07
- CUSIP
- G5269C101
Company
- Employees
- 366
- Headquarters
- London, United States
- Website
- https://www.kiniksa.com
- CEO
- Mr. Sanjiv K. Patel
Market
- Shares outstanding
- 48.3M
- Market cap
- $3.72B
Key dates
- Next earnings
- Oct 27, 2026
Highlights
- Market cap
- $3.63B
- EPS LTM
- $1.67calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- 46.08calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $840.85M+58.85%up year on year
- Net income
- $80.66M+1,583.88%up year on year
- Gross margin
- 54.49%+2.61%up year on year
- Free cash flow
- $183.1M+175.38%up year on year
Other listings
This company is not listed on any other exchange we cover.
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.